IL6 and retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and migraine headache syndrome: The current follow-up period under tocilizumab is still short (< 12 months), but the early anatomical response observed within one month suggests that IL-6 blockade may effectively suppress the underlying inflammatory component of ROSAH syndrome.